Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: Involvement of nuclear factor kappa B

Figure 2 Effects of SB203580, a specific p38 MAPK inhibitor, on the activation of p38 MAPK and NF-κB 14 d after the first immunization. A: Representative immunoprecipitate kinase activity assays of p38 MAPK using protein extracts from normal control, EAH mice treated with PBS, DMSO, and SB 203580, respectively; B: Western bolt of total p38 MAPK; C: Representative electrophoretic mobility shift assays of NF-κB DNA binding activity using nuclear protein extracts from liver of the 4 study groups as in A.